LeMaitre Vascular, Inc. (NASDAQ:LMAT) is Bridge City Capital LLC's 10th Largest Position

Bridge City Capital LLC cut its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 21.3% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 74,373 shares of the medical instruments supplier's stock after selling 20,098 shares during the quarter. LeMaitre Vascular accounts for 1.9% of Bridge City Capital LLC's investment portfolio, making the stock its 10th largest position. Bridge City Capital LLC owned about 0.33% of LeMaitre Vascular worth $6,240,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Allspring Global Investments Holdings LLC increased its stake in LeMaitre Vascular by 48.2% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 13,321 shares of the medical instruments supplier's stock worth $1,227,000 after buying an additional 4,330 shares in the last quarter. Invesco Ltd. raised its position in shares of LeMaitre Vascular by 50.5% in the fourth quarter. Invesco Ltd. now owns 174,998 shares of the medical instruments supplier's stock valued at $16,124,000 after buying an additional 58,720 shares during the last quarter. Barclays PLC lifted its stake in shares of LeMaitre Vascular by 394.5% in the third quarter. Barclays PLC now owns 36,577 shares of the medical instruments supplier's stock worth $3,396,000 after buying an additional 29,180 shares in the last quarter. Compass Planning Associates Inc acquired a new position in LeMaitre Vascular during the fourth quarter worth about $567,000. Finally, Teacher Retirement System of Texas grew its stake in LeMaitre Vascular by 31.8% during the 4th quarter. Teacher Retirement System of Texas now owns 101,851 shares of the medical instruments supplier's stock valued at $9,385,000 after acquiring an additional 24,586 shares in the last quarter. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 76,868 shares of the company's stock in a transaction dated Monday, May 19th. The stock was sold at an average price of $85.79, for a total transaction of $6,594,505.72. Following the sale, the chief executive officer now owns 1,796,783 shares in the company, valued at $154,146,013.57. This represents a 4.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Trent G. Kamke sold 2,009 shares of LeMaitre Vascular stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total value of $164,979.08. Following the completion of the transaction, the insider now owns 5,564 shares of the company's stock, valued at $456,915.68. The trade was a 26.53% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 102,009 shares of company stock worth $8,721,836 in the last ninety days. 9.50% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several research firms recently commented on LMAT. Oppenheimer cut LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Friday, February 28th. Lake Street Capital boosted their target price on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the company a "buy" rating in a report on Friday, February 28th. Wells Fargo & Company started coverage on shares of LeMaitre Vascular in a report on Thursday, February 13th. They set an "equal weight" rating and a $95.00 price target for the company. Finally, Barrington Research lowered shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Five analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. According to data from MarketBeat.com, LeMaitre Vascular presently has a consensus rating of "Hold" and an average target price of $97.83.

LeMaitre Vascular Price Performance

Shares of LMAT stock opened at $84.13 on Monday. LeMaitre Vascular, Inc. has a 1-year low of $71.42 and a 1-year high of $109.58. The firm has a market cap of $1.90 billion, a PE ratio of 45.97, a price-to-earnings-growth ratio of 2.22 and a beta of 0.83. The company has a 50-day moving average of $83.71 and a two-hundred day moving average of $90.91.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $0.48 earnings per share for the quarter, missing analysts' consensus estimates of $0.50 by ($0.02). The company had revenue of $59.87 million for the quarter, compared to analysts' expectations of $57.61 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The business's revenue for the quarter was up 12.0% on a year-over-year basis. During the same period in the previous year, the business posted $0.44 EPS. Sell-side analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, May 29th. Investors of record on Thursday, May 15th were paid a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a yield of 0.95%. The ex-dividend date was Thursday, May 15th. LeMaitre Vascular's payout ratio is currently 40.40%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.

Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.